IBIO 8-K 2026-11-10
iBio, Inc. (IBIO) 8-K dated 2026-11-10 — accession 0001420720-26-000035.
iBio, Inc. (IBIO) is a biotechnology company listed on US.
IBIO: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corpora…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
Not investment advice. The IBIO SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects to initiate first-in-human trials of IBIO-610 in the first half of 2027.
Why it matters
- expects to initiate first-in-human trials of IBIO-610 in the first half of 2027.
- This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesi…